LAKES COMMUNITY CENTER 

WHERE NATURE IS YOUR NEIGHBOR

Important Dates

Saturday - May 22

Trash Day @ LCC 9:00am

Thursday - June 3

Community Center Meeting @LCC 7:00pm

Saturday - June 5

Town Council @LCC 8:30am

Saturday - May 22

Trash Day @ LCC 9:00am

Thursday - June 3

Community Center Meeting @LCC 7:00pm

Saturday - June 5

Town Council @LCC 8:30am

Thursday - June 10

49er Committee Mtg. @LCC 7:00pm

Saturday- June 12

Chipping Day @LCC 9:00am - noon

SAFETY INFO
Check here for recent information on road closures, fires and weather updates.

BioLife reports increased usage of CryoStor and HypoThermosol biopreservation press products in clinical research BioLife Solutions, Inc levitraincanada.com . , a respected developer, manufacturer and internet marketer of proprietary clinical quality cell and cells hypothermic storage space and cryopreservation freeze press and a related cloud hosted biologistics cool chain administration app for wise shippers , today reported many new client disclosures on the usage of the Company's CryoStor and HypoThermosol biopreservation mass media products in pre-clinical validation tasks and clinical trials in the recent International Culture for Cellular Therapy conference.

site

Preclinical data show that BL-8040 effectively synergizes with Imatinib in-vitro1 and in-vivo, overcoming the protective aftereffect of the bone marrow, and we therefore wish that the mix of both of these drugs will override medication level of resistance and suppress residual disease,’ stated Prof. Nagler. ‘It really is conceivable that adding BL-8040 to Imatinib therapy in CML patients who’ve not achieved optimum cytogenetic or molecular responses may enhance their response to Imatinib by straight inducing apoptosis of the tumor cells and by mobilizing leukemic stem cells from the bone marrow's protective niches and sensitizing them to Imatinib-induced cell death.’.. BioLineRx to initiate Stage 1/2 clinical trial on new drug applicant for CML treatment BioLineRx , a clinical-stage biopharmaceutical firm dedicated to identifying, developing and in-licensing promising therapeutic applicants, today that Prof announced.